Robert Schmidt
Thorndale, PANPI 1811949381
Payments from drug & device makers
Across 294 payments — averaging $16.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$751
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$695
- Novo Nordisk$477
- GSK$294
- Johnson & Johnson$255
- plus $1K from 25 others
What the payments were for
- Food & beverage$4,85699%
- Education$401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 72 | $1,031 |
| AstraZeneca | 27 | $751 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 65 | $695 |
| Novo Nordisk | 8 | $477 |
| GSK | 14 | $294 |
| Johnson & Johnson | 16 | $255 |
| Pfizer | 11 | $186 |
| Boehringer Ingelheim | 10 | $172 |
| Merck | 8 | $139 |
| Lilly USA, LLC | 5 | $89 |
| Otsuka America Pharmaceutical, Inc. | 6 | $82 |
| E.r. Squibb & Sons, L.L.C. | 4 | $79 |
| Astellas Pharma US Inc | 5 | $67 |
| Philips North America LLC | 4 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $56 |
| Indivior Inc. | 3 | $55 |
| Mallinckrodt Enterprises LLC | 3 | $54 |
| Eisai Inc. | 3 | $51 |
| Mallinckrodt Hospital Products Inc. | 3 | $50 |
| Alkermes, Inc. | 3 | $45 |
| Biohaven Pharmaceuticals, Inc. | 3 | $43 |
| Qiagen, LLC | 2 | $34 |
| Galderma Laboratories, L.p. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Redhill Biopharma Inc. | 1 | $15 |
| MDD US Operations, LLC | 1 | $15 |
| Medline Industries LP | 1 | $14 |
| Biodelivery Sciences International, Inc. | 1 | $12 |
| Lundbeck LLC | 1 | $12 |
| Orexo US, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $1,021 |
| HumalogInsulin Lispro | 22 | $557 |
| Oxcarbazepine | 14 | $548 |
| Risperidone | 14 | $399 |
| Tamsulosin Hcl | 20 | $343 |
| Amlodipine Besylate | 29 | $318 |
| Lovastatin | 14 | $249 |
| Sertraline Hcl | 15 | $238 |
| Atorvastatin Calcium | 12 | $177 |
| Ropinirole Hcl | 26 | $153 |
| Bupropion XlBupropion Hcl | 13 | $99 |
| Furosemide | 14 | $68 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCHumalog | $89 | $55722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Pennsylvaniaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.